top of page
Gotham__Org Gotham White.png

Functional Assessment of Cancer Therapy – Prostate

For patients with Prostate cancer



Below are the details for the FACT-P measure:


Functional Assessment of Cancer Therapy – Prostate (FACT-P)






Prostate cancer patients 18 years and older


Past 7 days


5 point Likert-type scale


Paper and electronic


Self-administration and interview when applicable


Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Prostate Cancer Subscale


10-15 minutes


Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available.


Language Availability

Available translations of the FACT-P can be obtained by registering for permission. Users are not permitted to translate the FACT-P without permission from Permission from to translate the FACT-P may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system.

Please contact us for more information.

Language Availability


Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.

Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.

To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.

Selected References

Selected References

Beaumont, J., Butt, Z., Li, R., & Cella, D.  Meaningful Differences and Validity for the NCCN/FACT-P Symptom Index: An analysis of the ALSYMPCA data.  Cancer 2019; 125(11): 1877-1885.  doi: 10.1002/cncr.31973. 

Beer, T., Miller, K., Tombal, B., Cella, D., DePhung, Holmstrom, S., Ivanescu, C., Skaltsa, K., & Naidoo, S. The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies. European Journal of Cancer 2017; 87: 21-29.  doi: 10.1016/j.ejca.2017.09.035.

Cella, D., Petrylak, D., Fishman, M., Teigland, C., Young, J., & Mulani, P.  Role of quality of life in men with metastatic hormone-refactory prostate cancer: How does Astrsentan influence quality of life?  European Urology 2006; 49: 781-789.  doi: 10.1016/j.eururo.2005.12.05.

Cella, D., Nichol, M., Eton, D., Nelson, J., & Mulani, P.  Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy – Prostate: Results from a clinical trial of patients with metastatic hormone-refractory prostate cancer.  Value in Health 2009; 12(1): 124-129.

Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K.J.  Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) instrument.  Urology 1997; 50(6): 920-928.

Orakwe, D., Tijani, K., Jeje, E., Ogunjimi, M., Rufus, W., & Alab, T.  Bilateral Subcapsular Orchiectomy versus Bilateral Total Orchiectomy: Comparison of the Quality of Life Post‑Orchiectomy.  Nigerian Postgraduate Medical Journal 2018; 25(1): 43-47.  doi: 10.4103/npmj.npmj_169_17. 

Parker, C.,  Nilsson, s., Heinrich, D., Helle, S., O’Sullivan, J., Fosså, S., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D., Hoskin, P., Bottomley, D., James, N., Solberg, A., Syndikus, I., Kliment, J., Wedel,  S., Boehmer, S., Dall’Oglio, M., Franzén, L., Coleman, R., Vogelzang, N., O’Bryan-Tear, C., Staudacher, K.., Garcia-Vargas, J., Shan, M., Bruland, Ø.., & Sartor, O.  Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer.  The New England Journal of Medicine 2013; 369(3): 213-223.  doi: 10.1056/NEJMoa121375. 

Saad, F., Cella, D., Basch, E., Hadaschik, B., Mainwaring, P., Oudard, S., Graff, J., McQuarrie, K., Li, S., Hudgens, S. Lawson, J., Lopez-Gitlitz, A., Yu, M., Smith, M., & Small, E.  Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.  The Lancet Oncology 2018; 19(10):1404-1416.  doi: 10.1016/ S1470-2045(18)30567-9.

Sullivan, P.  Nelson, J., Mulani, P., & Slee, D.  Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer.  Quality of Life Research 2006; 15: 1297–1306.  doi: 10.1007/s11136-006-0003-2.

Vashistha, V., Singh, B., Kaur, S., Prokop, L., & Kaushik, D.  The Effects of Exercise on Fatigue, Quality of Life, and Psychological Function for Men with Prostate Cancer: Systematic Review and Meta-analyses.  European Urology Focus 2016; 2(3): 284-295.  doi: 10.1016/j.euf.2016.02.011.

Victorson, D., Beaumont, J, Rosenbloom, S., Shevrin, D, & Cella, D.  Efficient assessment of the most important symptoms in advanced prostate cancer: The NCCN/FACT-P symptom index.  Psycho-Oncology 2011; 20(9): 977-983.  doi: 10.1002/pon.1817.

Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R.  Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system.  Quality of Life Research 1996; 5: 309-320.

Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232.

Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85.

Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191.

Related Measures

Related Measures


Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 7 Item Version


National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index - 17 Item Version


Functional Assessment of Cancer Therapy – Radionuclide Therapy

bottom of page